Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892426 | PMC |
| http://dx.doi.org/10.1093/ckj/sfaf038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Does low-dose spironolactone increase cardiovascular protection in patients with chronic kidney disease?
Clin Kidney J
March 2025
1st Department of Nephrology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
Spironolactone reduces the risk of low-dose oral minoxidil-induced edema in women with female pattern hair loss.
J Am Acad Dermatol
February 2025
Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain; Hair Disorder Unit, Grupo Pedro Jaén, Madrid, Spain.
Corticosteroid receptor antagonism in the medial prefrontal cortex reduces morphine-induced place preference and dopamine transporter expression decline in rats.
Neuroscience
February 2025
Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran; Department of Physiology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran. Electronic address:
Corticosteroid signaling plays a critical role in modulating the neural systems underlying reward and addiction, but the specific contributions of glucocorticoid receptors (GRs) and mineralocorticoid receptors (MRs) in the medial prefrontal cortex (mPFC) to opioid reward and dopaminergic plasticity remain unclear. Here, we investigated the effects of intra-mPFC injection of corticosteroid receptor ligand (corticosterone; CORT), glucocorticoid receptor antagonist (RU38486; RU), and mineralocorticoid receptor antagonist (spironolactone; SP) on morphine-induced conditioned place preference (CPP) and dopamine transporter (DAT) expression in the mPFC. Adult male Wistar rats received intra-mPFC injections of CORT, RU, SP, or their respective vehicles prior to morphine CPP conditioning.
View Article and Find Full Text PDFImproving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy: A retrospective review.
JAAD Int
December 2024
Ronald O. Perelman Department of Dermatology, University Grossman School of Medicine, New York, New York.
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
Nat Med
December 2024
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Article Synopsis
- * In a trial involving 1,372 participants, spironolactone did not show a significant reduction in cardiovascular incidents compared to usual care, with similar events occurring in both groups over three years.
- * Many participants discontinued spironolactone due to safety concerns, particularly related to decreases in kidney function and side effects, leading to the conclusion that it may not be a suitable treatment for this population.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!